Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Marco RussanoAlessio CortelliniRaffaele GiustiAlessandro RussoFederica ZorattoFrancesca RastelliAlain GelibterRita ChiariOlga NigroMichele De TursiSergio BracardaStefania GoriFrancesco GrossiMelissa BersanelliLorenzo CalvettiVincenzo Di NoiaMario ScartozziMassimo Di MaioPaolo BossiAlfredo FalconeFabrizio CitarellaFrancesco PantanoCorrado FicorellaMarco FilettiVincenzo AdamoEnzo VeltriFederica PergolesiMario Alberto OcchipintiLinda NicolardiAlessandro TuziPietro Di MarinoSerena MacriniAlessandro InnoMichele GhidiniSebastiano ButiGiuseppe AprileEleonora LaiMarco AudisioSalvatore IntagliataRiccardo MarconciniDavide BroccoGiampiero PorzioMarta PirasErika RijavecFrancesca SimionatoClara NatoliMarcello TiseoBruno VincenziGiuseppe ToniniDaniele SantiniPublished in: Cancer immunology, immunotherapy : CII (2021)
We found no survival benefit in LTD cohort compared to the control cohort. However, early and severe irAEs might underly an immune anti-tumor activation. We identified a significant association with first-line immune checkpoints inhibitors treatment and good PS. Further studies on risk prediction and management of serious and early irAEs in NSCLC patients are needed.